Trials / Recruiting
RecruitingNCT06979362
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 40 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDR132L | CDR132L will be administered intravenously once every 4 weeks. |
| DRUG | Placebo | Placebo will be administered intravenously once every 4 weeks. |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2027-05-16
- Completion
- 2028-01-23
- First posted
- 2025-05-19
- Last updated
- 2026-03-11
Locations
109 sites across 9 countries: United States, Canada, Germany, India, Japan, Poland, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06979362. Inclusion in this directory is not an endorsement.